0	15	Transcriptional	transcriptional	JJ
16	19	and	and	CC
20	39	posttranscriptional	posttranscriptional	JJ
40	50	regulation	regulation	NN
51	53	of	of	IN
54	63	erythroid	erythroid	JJ
64	68	gene	gene	NN
69	79	expression	expression	NN
80	82	in	in	IN
83	104	anthracycline-induced	anthracycline-induced	JJ
105	120	differentiation	differentiation	NN
121	123	of	of	IN
124	129	human	human	JJ
130	145	erythroleukemic	erythroleukemic	JJ
146	151	cells	cell	NNS
151	152	.	.	.

154	167	Aclacinomycin	Aclacinomycin	NNP
168	169	(	(	(
169	173	ACLA	ACLA	NNP
173	174	)	)	)
175	178	and	and	CC
179	190	doxorubicin	doxorubicin	NN
191	192	(	(	(
192	195	DOX	DOX	NNP
195	196	)	)	)
197	201	were	be	VBD
202	206	used	use	VBN
207	209	at	at	IN
210	218	subtoxic	subtoxic	JJ
219	233	concentrations	concentration	NNS
234	236	to	to	TO
237	243	induce	induce	VB
244	253	erythroid	erythroid	JJ
254	269	differentiation	differentiation	NN
270	272	in	in	IN
273	276	the	the	DT
277	282	human	human	JJ
283	291	leukemic	leukemic	JJ
292	296	cell	cell	NN
297	301	line	line	NN
302	306	K562	k562	NN
306	307	.	.	.

308	312	Cell	cell	NN
313	330	hemoglobinization	hemoglobinization	NN
331	334	was	be	VBD
335	346	accompanied	accompany	VBN
347	349	by	by	IN
350	353	the	the	DT
354	363	increased	increase	VBN
364	374	expression	expression	NN
375	377	of	of	IN
378	383	genes	gene	NNS
384	392	encoding	encode	VBG
393	405	gamma-globin	gamma-globin	NN
406	409	and	and	CC
410	425	porphobilinogen	porphobilinogen	NN
426	435	deaminase	deaminase	NNP
436	437	(	(	(
437	441	PBGD	PBGD	NNP
441	442	)	)	)
442	443	,	,	,
444	446	an	an	DT
447	453	enzyme	enzyme	NN
454	456	of	of	IN
457	461	heme	heme	NN
462	471	synthesis	synthesis	NN
471	472	.	.	.

473	475	By	by	IN
476	481	using	use	VBG
482	488	run-on	run-on	JJ
489	495	assays	assay	NNS
495	496	,	,	,
497	501	ACLA	ACLA	NNP
502	505	was	be	VBD
506	511	shown	show	VBN
512	514	to	to	TO
515	521	induce	induce	VB
522	524	an	an	DT
525	536	enhancement	enhancement	NN
537	539	of	of	IN
540	543	the	the	DT
544	557	transcription	transcription	NN
558	560	of	of	IN
561	570	erythroid	erythroid	JJ
571	576	genes	gene	NNS
576	577	,	,	,
578	587	including	include	VBG
588	600	gamma-globin	gamma-globin	NN
600	601	,	,	,
602	606	PBGD	PBGD	NNP
606	607	,	,	,
608	622	erythropoietin	erythropoietin	NN
623	631	receptor	receptor	NN
631	632	,	,	,
633	636	and	and	CC
637	643	GATA-1	gata-1	NN
644	657	transcription	transcription	NN
658	664	factor	factor	NN
664	665	.	.	.

666	668	In	in	IN
669	677	contrast	contrast	NN
677	678	,	,	,
679	681	in	in	IN
682	693	DOX-treated	dox-treated	JJ
694	699	cells	cell	NNS
699	700	,	,	,
701	704	the	the	DT
705	718	transcription	transcription	NN
719	723	rate	rate	NN
724	726	of	of	IN
727	732	these	these	DT
733	738	genes	gene	NNS
739	742	was	be	VBD
743	752	unchanged	unchanged	JJ
753	755	in	in	IN
756	766	comparison	comparison	NN
767	771	with	with	IN
772	779	control	control	NN
780	785	cells	cell	NNS
785	786	.	.	.

787	789	In	in	IN
790	798	addition	addition	NN
798	799	,	,	,
800	810	inhibition	inhibition	NN
811	813	of	of	IN
814	818	mRNA	mrna	NN
819	828	synthesis	synthesis	NN
829	833	with	with	IN
834	845	actinomycin	actinomycin	NN
846	847	D	D	NNP
848	857	indicated	indicate	VBD
858	862	that	that	IN
863	866	DOX	DOX	NNP
867	874	induced	induce	VBD
875	877	an	an	DT
878	887	increased	increase	VBN
888	897	stability	stability	NN
898	900	of	of	IN
901	905	PBGD	PBGD	NNP
906	909	and	and	CC
910	916	GATA-1	gata-1	NN
917	922	mRNAs	mrna	NNS
922	923	,	,	,
924	931	whereas	whereas	IN
932	936	ACLA	ACLA	NNP
937	940	did	do	VBD
941	944	not	not	RB
945	951	affect	affect	VB
952	955	the	the	DT
956	966	half-lives	half-live	NNS
967	969	of	of	IN
970	975	these	these	DT
976	981	mRNAs	mrna	NNS
981	982	.	.	.

983	990	Because	because	IN
991	994	the	the	DT
995	1003	increase	increase	NN
1004	1006	in	in	IN
1007	1016	erythroid	erythroid	JJ
1017	1021	mRNA	mrna	NN
1022	1034	steady-state	steady-state	JJ
1035	1040	level	level	NN
1041	1043	in	in	IN
1044	1065	anthracycline-treated	anthracycline-treated	JJ
1066	1071	cells	cell	NNS
1072	1075	was	be	VBD
1076	1085	inhibited	inhibit	VBN
1086	1088	by	by	IN
1089	1102	cycloheximide	cycloheximide	NN
1102	1103	,	,	,
1104	1108	this	this	DT
1109	1117	suggests	suggest	VBZ
1118	1122	that	that	IN
1123	1138	transcriptional	transcriptional	JJ
1139	1149	activation	activation	NN
1150	1152	in	in	IN
1153	1165	ACLA-treated	acla-treated	JJ
1166	1171	cells	cell	NNS
1172	1175	and	and	CC
1176	1180	mRNA	mrna	NN
1181	1194	stabilization	stabilization	NN
1195	1197	in	in	IN
1198	1209	DOX-treated	dox-treated	JJ
1210	1215	cells	cell	NNS
1216	1220	were	be	VBD
1221	1230	dependent	dependent	JJ
1231	1233	on	on	IN
1234	1236	de	de	FW
1237	1241	novo	novo	FW
1242	1249	protein	protein	NN
1250	1259	synthesis	synthesis	NN
1259	1260	.	.	.

1261	1268	Finally	finally	RB
1268	1269	,	,	,
1270	1276	GATA-1	gata-1	NN
1277	1284	protein	protein	NN
1285	1290	level	level	NN
1291	1294	was	be	VBD
1295	1300	shown	show	VBN
1301	1303	to	to	TO
1304	1306	be	be	VB
1307	1316	increased	increase	VBN
1317	1319	in	in	IN
1320	1332	ACLA-treated	acla-treated	JJ
1333	1336	but	but	CC
1337	1340	not	not	RB
1341	1343	in	in	IN
1344	1355	DOX-treated	dox-treated	JJ
1356	1361	cells	cell	NNS
1361	1362	.	.	.

1363	1368	These	these	DT
1369	1372	two	two	CD
1373	1387	anthracyclines	anthracycline	NNS
1387	1388	,	,	,
1389	1397	although	although	IN
1398	1405	closely	closely	RB
1406	1413	related	related	JJ
1414	1416	in	in	IN
1417	1422	their	their	PRP$
1423	1433	structures	structure	NNS
1433	1434	,	,	,
1435	1443	appeared	appear	VBD
1444	1446	to	to	TO
1447	1450	act	act	VB
1451	1453	as	as	IN
1454	1469	differentiation	differentiation	NN
1470	1478	inducers	inducer	NNS
1479	1481	by	by	IN
1482	1490	distinct	distinct	JJ
1491	1501	mechanisms	mechanism	NNS
1501	1502	.	.	.

1503	1509	Indeed	indeed	RB
1509	1510	,	,	,
1511	1520	erythroid	erythroid	JJ
1521	1525	gene	gene	NN
1526	1536	expression	expression	NN
1537	1540	was	be	VBD
1541	1553	demonstrated	demonstrate	VBN
1554	1556	to	to	TO
1557	1559	be	be	VB
1560	1569	regulated	regulate	VBN
1570	1587	transcriptionally	transcriptionally	RB
1588	1590	by	by	IN
1591	1595	ACLA	ACLA	NNP
1596	1599	and	and	CC
1600	1606	mainly	mainly	RB
1607	1628	posttranscriptionally	posttranscriptionally	RB
1629	1631	by	by	IN
1632	1635	DOX	DOX	NNP
1635	1636	.	.	.